<DOC>
	<DOCNO>NCT00408148</DOCNO>
	<brief_summary>The objective study evaluate effect Rimonabant 20mg comparison placebo , HDL VLDL lipoprotein kinetics , 12 month period . Primary objective : - To assess effect Rimonabant HDL ApoA-I fractional catabolic rate ( FCR ) . Secondary objective : - To assess effect Rimonabant HDL ApoA-I production rate ( PR ) lipoprotein kinetics . - To assess effect Rimonabant lipid , glycemic inflammatory parameter - To assess effect Rimonabant body composition - To assess safety Rimonabant</brief_summary>
	<brief_title>High Density Lipoprotein Turnover</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Abdominally obese patient additional cardiometabolic risk factor Females must postmenopausal BMI &gt; 27 kg/m² &lt; 40 kg/m² Men woman abdominal obesity accord NCEP/ATPIII criterion : Waist Circumference &gt; 88 cm woman ; &gt; 102 cm men With least one lipid abnormality define : Fasting Triglycerides level &gt; 1.7 mmol/L ( 150 mg/dL ) &lt; 4.5 mmol/L ( 400 mg/dL ) HDL &lt; 1.03 mmol/L ( 40 mg/dL ) men &lt; 1.29 mmol/L ( 50 mg/dL ) woman HDL ≤ 0.60 mmol/L ( 23 mg/dl ) Plasma LDLCholesterol &gt; 155 mg/dl ( 4.00 mmol/L ) total cholesterol 250 mg/dl ( &gt; 6.5mmol/L ) genetic hyperlipidaemia Fasting triglycerides &gt; 400 mg/dL ( 4.5 mmol/L ) Known heterozygous homozygous familial hypercholesterolaemia know type III hyperlipoproteinaemia ( familial dysbetalipoproteinaemia ) ApoE2/E2 homozygosity , Apo E4/E4 homozygosity Type 2 diabetes treat oral agent and/or insulin Diet treat type 2 diabetic patient HbA1c ≥ 7 % History cardio vascular disease Systolic blood pressure ≥ 160 mmHg diastolic blood pressure ≥ 95 mmHg . Very lowcalorie diet ( 1200 calorie day less ) history surgical procedure weight loss ( e.g. , stomach stapling , bypass ) Body weight fluctuation &gt; 5 Kg previous 3 month History bulimia anorexia nervosa DSMIV criterion Presence clinically significant endocrine disease accord investigator , Cushing syndrome , obesity secondary hypothalamic/pituitary disorder . Abnormal TSH free T4 baseline ( Patients treat thyroid replacement therapy must fix stable dose least 3 month prior screen must euthyroïd status . ) Severe hepatic impairment know investigator AST ALT &gt; 3 time ULN screening . Known severe renal dysfunction ( creatinine clearance &lt; 30 ml/min ) urine analysis ( perform screen dipstick ) show 2+ protein Presence condition ( medical , include clinically significant abnormal laboratory test , psychological , social geographical ) actual anticipate investigator feel would compromise patient safety limit his/her successful participation study Patient treat epilepsy Ongoing major depressive illness Uncontrolled psychiatric illness History alcohol and/or drug abuse Smoker smoking cessation within past 3 month Marijuana hashish user Previous participation Rimonabant study clinical trial within 4 week study start Hypersensitivity/intolerance active substance excipients lactose Blood donation within past 3 month prior study plan study within 3 month study complete Recent history active peptic ulcer Willebrand disease hemorrhagic diatheses Administration follow within 3 month prior screen visit susceptible prescribed study treatment period : Lipidlowering drug intake Anti obesity drug Other drug weight reduction ( phentermine , amphetamine ) Herbal preparation weight reduction Other drug know affect lipid metabolism : retinoids , antiretroviral , estrogens hormone replacement therapy , cyclosporine , glitazones , benfluorex , fish oil , plant sterol . Thiazids ( include fix combination ) daily dose high 12.5 mg Unselective betablockers Prolonged use ( one week ) systemic corticosteroid , neuroleptic Anticoagulants Ongoing antidepressive treatment The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>